RxDoctor Payments Data

Diana Mercado, MD

Infectious Disease · Jacksonville, FLNPI 1255543849

Payments from drug & device makers

$1,106in general payments, 2019–2025

Across 43 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$230
  • AbbVie$169
  • Merck$152
  • Paratek Pharmaceuticals, Inc.$109
  • Theratechnologies Inc.$104
  • Aimmune Therapeutics, Inc.$77
  • plus $265 from 6 others

What the payments were for

  • Food & beverage$1,106100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,106 in reported general payments places this provider in the 50th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$149,124
Medicare patients
360
Services billed
1,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DescovyEmtricitabine/Tenofov Alafenam26$66,287
DovatoDolutegravir Sodium/Lamivudine20$64,137
GenvoyaElviteg/Cob/Emtri/Tenof Alafen14$56,517
TivicayDolutegravir Sodium16$45,372
Daptomycin15$32,503
ErtapenemErtapenem Sodium21$9,771
Atovaquone13$9,657
Vancomycin Hcl24$4,188
Cefazolin Sodium23$1,739
Cefepime Hcl12$1,591
CeftriaxoneCeftriaxone Sodium24$1,513
Doxycycline Hyclate33$877
Cefdinir19$314
Amoxicillin12$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadDescovy, Genvoya$230$122,80440 claims
Viiv Healthcare CompanyDovato, Tivicay$60$109,50936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →